COINFECTION BY HEPATITIS-B VIRUS AND HEPATITIS-C VIRUS IN RENAL-TRANSPLANTATION - MORBIDITY AND MORTALITY IN 1098 PATIENTS

The aim of the study was to analyse the influence of co-infection by h epatitis B virus (HBV) and hepatitis C virus (HCV) as compared with HC V infection alone in 1098 patients who received a kidney transplant be tween 1 January and 31 December 1991. At transplantation, the prevalen ce of anti-HCV antibodies was 21.40% (235/1098) while the prevalence o f HBV infection was 9.85% (108/1096); 46 patients were co-infected wit h HBV and HCV, either 19.70% of HCV-infected patients and 42.60% of HB V-infected patients. Liver tests, galactose clearance and liver biopsy were compared in the 46 co-infected patients (HCV+HBV+) and in the 18 9 HCV-infected patients (HCV+HBV-). At the time of transplantation, cy tolysis was present in 31.45% of HCV+HBV- patients (50/159) and in 40% of HCV+HBV- patients (16/40); cholestasis was present in 34.18% of HC V+HBV- patients (34/158) and 42.11% of HCV+HBV+ patients (16/38). At 6 months the incidence of biological abnormalities increased to 37% in HCV+HBV- patients (55/150) and to 52.5% in HCV+HBV+ patients (21/40), suggesting a more deleterious effect of the immunosuppressive therapy in the co-infected group. Over the course of transplantation, chronic hepatitis was present in 50% of HCV+HBV- patients and in 64.1% of HCVHBV+ patients. Liver failure occurred in 7% of HCV+HBV- patients (12/1 56) and 17% of HCV+HBV+ patients (7/41). Galactose clearance was perfo rmed as a functional test in 68 patients: it was not significantly dif ferent in either group. Liver biopsy was performed in 108 patients at least once. Minimal changes were more frequent in HCV+HBV- patients wh ile the incidence of cirrhosis was 10% in HCV+HBV- patients (8/81) and 26% in HCV+HBV+ patients (7/27). Serum HCV RNA detected by polymerase chain reaction was present in 81% of the HCV+HBV- patients (43/53) an d 70% of the HCV+HBV+ patients (14/20). Patient survival rate was not significantly different in both groups at 12 years.